Publications: Douglas McNeel, M.d. Ph.D.

Bibliography and peer-reviewed publications

Peer-reviewed publications of original work

  1. Zahm CD, Johnson LE, and McNeel DG.  (2019)  “Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.”  Cancer Immunol Immunoth 68:1661-1669.  (PMID: 31606777, PMCID: pending)
  2. McNeel DG, Eickhoff JC, Johnson LE, Roth AR, Perk TG, Fong L, Antonarakis ES, Wargowski E, Jeraj R, and Liu G.  (2019)  “Randomized phase 2 trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP, MVI-816) in patients with progressive non-metastatic, castration-sensitive prostate cancer.”  J Clin Oncol  37:3507-3517.  (PMID: 31644357, PMCID: pending)
  3. Scarpelli M, Zahm CD, Perlman S, McNeel DG, Jeraj R, and Liu G.  (2019)  “FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab.”  Journal ImmunoTherapy of Cancer 7:23.  (PMID: 30700328, PMCID: PMC6354338)
  4. Zahm CD, Colluru VT, McIlwain SJ, Ong IM, and McNeel DG.  (2018)  “TLR stimulation during T-cell activation lowers PD-1 expression on CD8+ T cells.”  Canc Imm Res 6:1364-1374.  (PMID: 30201735, PMCID: PMC6215515)
  5. McNeel DG, Eickhoff JC, Wargowski E, Zahm CD, Staab MJ, Straus J, and Liu G.  (2018)  “Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer.”  Oncotarget 9:25586-25596.  (PMID: 29876010, PMCID: PMC5986652)
  6. Johnson LE, Brockstedt D, Leong M, Lauer P, Theisen E, Sauer J-D, and McNeel DG.  (2018)  “Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming.”  Oncoimmunology 7:e1456603.  (PMID: 30221049, PMCID: PMC6136874)
  7. Zahm CD, Colluru VT, and McNeel DG.  (2017)  “Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8+ T cells”  Canc Imm Res 5:630-641.  (PMID: 28634215, PMCID: PMC5821110)
  8. Olson BM, Bradley E, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru V, Johnson LE, Rekoske BT, Eickhoff JC, and McNeel DG.  (2017)  “Safety and immunological efficacy of a DNA vaccine encoding the androgen receptor ligand-binding domain (AR-LBD).”  Prostate 77:812-821.  (PMID 28181678, PMCID: PMC5382038)
  9. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, and Gulley JL. (2016) “The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Prostate Carcinoma.”  J ImmunoTherapy Cancer 4:92-103.  (PMID: 28031820, PMCID: PMC5170901)
  10. Colluru VT and McNeel DG.  (2016)  “B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.”  Oncotarget 7:67901-67918.  (PMID: 27661128, PMCID: PMC5356528)
  11. Colluru VT, Zahm CD, and McNeel DG.  (2016)  “Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8 T cells and inferior anti-tumor responses.”  Oncoimmunology 5:e1223002.  (PMID: 27853647, PMCID: PMC5087309)
  12. Rekoske BT, Olson BM, and McNeel DG.  (2016)  “Anti-tumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.”  Oncoimmunology 5:e1165377.  (PMID: 27471641, PMCID: PMC4938302)
  13. Rekoske BT, Smith HA, Olson BM, Maricque BB, and McNeel DG.  (2015)  “PD-1 or PD-L1 blockade restores anti-tumor efficacy following SSX2 epitope-modified DNA vaccine immunization.”  Canc Imm Res 3:946-955.  (PMID: 26041735, PMCID: PMC4527948)
  14. McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, and Olson BM.  (2014)  “Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase (PAP) in patients with castration-resistant prostate cancer.”  Clin Can Res 20:3692-3704.  (PMID: 24850844, PMCID: PMC4102643)
  15. Smith HA, Rekoske BT, McNeel DG.  (2014)  “DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.”  Vaccine 32:1707-1715.  (PMID:  24492013, PMCID:  PMC4153342)
  16. Johnson LE, Becker JT, Dubovsky JA, Olson BM, and McNeel DG.  (2013)  “Prostate carcinoma in transgenic Lewis rats – A tumor model for evaluation of immunological treatments.”  Chin. Clin. Oncol.  2:4-12 (  (PMID: 24324949, PMCID: PMC3855422).
  17. Olson BM, Jankowska-Gan E, Becker JT, Vignali DAA, Burlingham WJ, and McNeel DG.  (2012)  “Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.”  J. Immunol.  189:5590-5601.  (PMID: 23152566, PMCID: PMC3735346)
  18. Olson BM, Johnson LE, and McNeel DG.  (2013)  “The androgen receptor – a biologically-relevant vaccine target for the treatment of prostate cancer.”  Cancer Immunol. Immunoth.  62:585-596.  (PMID: 23108626, PMD: PMC3577997)
  19. Johnson LE and McNeel DG.  (2012)  “Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.”  Prostate  72:730-740.  (PMID: 22529020)
  20. Olson BM and McNeel DG.  (2011)  “CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.”  Cancer Immunol. Immunoth.  60:781-792.  (PMID: 21350948, PMCID: PMC3319721).
  21. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, and McNeel DG.  (2010)  “DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.”  J Immunotherapy 33:639-647.  (PMID 20153396, PMCID: PMC3045767).
  22. Morse MD and McNeel DG.  (2010)  “Prostate cancer patients treated with androgen deprivation therapy develop persistent changes in adaptive immune responses.”  Human Immunology  71:496-504.  (PMID 20153396, PMCID: PMC2856724)
  23. Olson BM, Frye TP, Johnson LD, Fong L, Knutson KL, Disis ML, and McNeel DG.  (2010) “HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.”  Cancer Immunol. Immunother.  59:943-953.  (PMID 20140431, PMCID: PMC3038205)
  24. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, and Wilding G.  (2009)  “Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.”  J. Clin. Oncol. 27:4047-4054.  (PMID: 19636017, PMCID:  PMC2734418)
  25. Olson BM and McNeel DG.  (2007)  “Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.”  Prostate 67:1729-1739.  (PMID:  17879963)
  26. Johnson LE, Frye TP, Chinnasamy D, Chinnasamy N, and McNeel DG.  (2007)  “Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) effective in eliciting autologous antigen-specific CD8 T cells.”  Cancer Immunol Immunother  56:885-895.  (PMID:  17102977)
  27. Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DG.  (2006)  “Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).”  Vaccine 24:293-303.  (PMID:  16115700)
  28. Zlotocha S, Staab MJ, Horvath D, Straus J, Dobratz J, Oliver K, Wasielewski S, Alberti D, Liu G, Wilding G, Eickhoff J, and McNeel DG.  (2005)  “A phase I study of a DNA vaccine targeting prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.”  Clin. Genitourinary Cancer  4:215-218.  (PMID:  16425992)

Invited, peer-reviewed, review articles or editorials

  1. Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, and Gulley JL.  (2020)  “Putting the pieces together:  Completing the mechanism of action jigsaw for sipuleucel-T.”  J Natl Cancer Inst (pending).  (PMID: 32145020, PMCID: exempt).
  2. McNeel DG.  (2018)  “Therapeutic Cancer Vaccines:  How Much Closer Are We?”  BioDrugs 32:1-7.  (PMID 29285731, PMCID: PMC5815920)
  3. Gamat M and McNeel DG.  (2017)  “Androgen deprivation and immunotherapy for the treatment of prostate cancer.”  Endocrine-Related Cancer 24:T297-T310.  (PMID: 28814451, PMCID: PMC5669826)
  4. Zahm CD, Colluru VT, and McNeel DG.  (2017)  “DNA vaccines for prostate cancer.”  Pharmacol Ther 174:27-42.  (PMID: 28185916, PMCID:  PMC5429198)
  5. Colluru VT, Johnson LE, Olson BM, and McNeel DG.  (2016)  “Preclinical and clinical development of DNA vaccines for prostate cancer.”  Urol. Oncol. 34:193-204.  (PMID: 24332642, PMCID: PMC4053490)
  6. Olson BM and McNeel DG.  (2013)  “Monitoring regulatory immune responses in tumor immunotherapy clinical trials.”  Front. Oncol. 3:1-11. (PMID: 23653893, PMCID: PMC3644716)
  7. Bruce JY, Lang JM, McNeel DG, and Liu G.  (2012)  “Current controversies in the management of biochemical failure in prostate cancer.”  Clin. Adv. Hematol. Oncol. 10:716-722.  (PMID: 23271258)
  8. McNeel DG, Becker JT, Johnson LE, and Olson BM.  (2012)  “DNA vaccines for prostate cancer.”  Curr. Cancer Ther. Rev. 8:245-253.  (PMID: 24587772, PMCID: PMC3935480)
  9. Alam S and McNeel DG.  (2010)  “DNA vaccines for the treatment of prostate cancer.”  Exp. Rev. Vaccines  9:731-745.  (PMID: 20624047)

Invited, peer-reviewed book chapters

  1. Bradley ES and McNeel DG.  “DNA Vaccines.”  Marshall JL ed. Encyclopedia of Cancer Therapeutic Targets.  New York:  Springer, 2016.
  2. Olson BM and McNeel DG.  “Engineering DNA vaccines for cancer therapy.”  Cai W ed.  Engineering in Translational Medicine, Chapter 17.  London:  Springer-Verlag, 2014.  
  3. Olson BM and McNeel DG.  “Methods for constructing and evaluating anti-tumor DNA vaccines.”  Walther W, Stein US eds.  Methods in Molecular Biology, Gene Therapy of Cancer, vol. 542.  Totowa: Humana Press, 2009 p. 211-243.  (PMID:  19565905)
  4. McNeel DG.  “Prostate cancer antigens and vaccines, preclinical developments.”  In:  Giaccone G, Schilsky R, Sondel P. eds.  Cancer Chemotherapy and Biological Response Modifiers, Annual 22.  Oxford:  Elsevier Limited, 2005 p. 247-261.  (PMID:  16110615)

Get in touch

Need help with something specific? Send us a message.

Contact us

Current clinical trials

Get more information on the clinical trials we have in progress.

See Clinical Trials

Our therapies

Learn more about our current product line.

Learn More